In this article, network pharmacology analysis showed that RR's core targets for ESCC were CCNA2, CCNB2, CDK2, and CHEK1, and its inhibitory effect on ESCC was enriched in a variety of signaling pathways, mainly focusing on cell cycle signaling pathway and also affecting p53 signaling pathway. This evidence concerns the gene CCNA2 and esophageal squamous cell carcinoma.